Archive: Company News
Launch of Capitainer® B Vanadate, a blood sampling card that eliminates the risk of inaccurate test results when analyzing PEth
Swedish medtech scaleup Capitainer today announced the launch of its proprietary patent pending blood sampling card, Capitainer B Vanadate for accurate analysis of PEth, a key marker for long term alcohol use/abuse.
Dried Blood Spot (DBS) sampling has been proposed as a method to solve the problem of post sampling formation of PEth occurring in traditional venous blood samples. However, the hematocrit effect gives negative impact on the accuracy due to uncertainty of the blood volume in DBS. Capitainer B Vanadate solves both problems in the same device and creates a new better standard.
T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
— Presentations to cover preclinical data for lead TCR-T candidate, TK-8001, and the protocol design for a Phase 1/2 trial of TK-8001 to treat MAGE-A1 positive solid tumors
T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced that three abstracts highlighting its lead product candidate TK-8001, a T cell receptor (TCR) engineered T cell therapy (TCR-T) being developed to treat MAGE-A1 positive solid tumors, will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting taking place November 10-14, 2021.
ImmunOs Therapeutics Appoints Claudia Berger as SVP Clinical Development
– Strengthened clinical development expertise to ensure smooth transition into the clinic
Schlieren (Zurich Area), Switzerland. ImmunOs Therapeutics AG, a Swiss biotechnology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, today announced that Claudia Berger has been appointed as Senior Vice President Clinical Development, further strengthening the Company’s clinical development and operations expertise as it prepares for initial clinical trials.
BellaSeno Receives Australian Public Grant Totaling AUD 1 Million
— Winner of the Australian Global Innovation Linkages Program
— Funding dedicated to advancing regenerative scaffolds for breast reconstruction and large bone defects
— BellaSeno to lead consortium of renowned commercial and academic partners
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that its Australian subsidiary BellaSeno Pty Ltd has been granted AUD 1 million (EUR 625,600) for the development of regenerative scaffolds for breast reconstruction and large bone defects. The grant was provided under the Australian Global Innovation Linkages Program, which is dedicated to help Australian businesses and researchers collaborate with global partners.